Core Laboratories N.V. (CLB) Tops Q3 EPS by 1c; Raises FY11 EPS Outlook, Guides Q4
Tweet
Share
E-mailGet Alerts CLB Hot Sheet
Join SI Premium – FREE
Core Laboratories N.V. (NYSE: CLB) reported Q3 EPS of $1.00, $0.01 better than the analyst estimate of $0.99. Revenue for the quarter came in at $231.34 million versus the consensus estimate of $238.07 million.
Core Laboratories N.V. sees Q4 2011 EPS of $1.06-$1.08, versus prior guidance of $252.24 and the consensus of $1.08. Core Laboratories N.V. sees Q4 2011 revenue of $240-$246 million.
Core Laboratories N.V. sees FY2011 EPS of $3.73-$3.75, versus prior guidance of $3.65-$3.72 and the consensus of $3.75. Core Laboratories N.V. sees FY2011 revenue of $904-$910 million, versus the consensus of $923.48 million.
Core Laboratories N.V. sees Q4 2011 EPS of $1.06-$1.08, versus prior guidance of $252.24 and the consensus of $1.08. Core Laboratories N.V. sees Q4 2011 revenue of $240-$246 million.
Core Laboratories N.V. sees FY2011 EPS of $3.73-$3.75, versus prior guidance of $3.65-$3.72 and the consensus of $3.75. Core Laboratories N.V. sees FY2011 revenue of $904-$910 million, versus the consensus of $923.48 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
- Pulmatrix (PULM) Reports Q2 Loss of $0.29
- Forum Markets, Incorporated (FRMM) Tops Q2 EPS by 29c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
